Entera Bio Ltd. WT EXP 062723
ENTXW
NASDAQ Capital Market0.00
USD
+0.00
- -
Entera Bio Ltd. WT EXP 062723
ENTXW
(NASDAQ Capital Market)
Recent
price
0.00
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Entera Bio Ltd. is a clinical-stage biopharmaceutical company specializing in the development of novel therapeutics for metabolic and endocrine disorders. Its main product pipeline features orally available peptide-based therapeutics including formulations designed to treat diabetes, obesity, and osteoporosis. The company’s core offerings encompass peptide drug development, oral delivery technology for peptide therapeutics, and proprietary new chemical entities designed to improve patient compliance and treatment outcomes. Entera Bio’s solutions bridge the gap between injectable biologics and oral medication by leveraging its patented permeation technologies. Headquartered in Israel and founded in 2002, Entera Bio operates primarily in the biopharmaceutical industry, targeting global markets focused on metabolic diseases and rare endocrine conditions. It engages in clinical trials and product development partnerships to advance its drug candidates toward regulatory approval. In the latest corporate developments as of 2024–2025, Entera Bio secured strategic partnerships to expand its clinical pipeline and manufacturing capabilities. The company has announced new funding rounds aimed at accelerating phase II and III clinical trials and has advanced several key product candidates into late-stage clinical testing. This includes a strategic alliance to enhance its oral calcitonin program for osteoporosis treatment and a collaborative effort to broaden the indication scope for its diabetes drug candidates. These efforts underscore Entera Bio’s strategic shift to strengthen its presence in metabolic and endocrine therapy markets while expanding its geographic operations beyond its base in Israel. Overall, Entera Bio Ltd.’s product offerings integrate peptide therapeutics, oral delivery systems, and disease-specific treatment candidates, supported by recent financial and strategic activities focused on advancing its clinical pipeline and market footprint.